Range Cancer Therapeutics ETF Stock Price, News & Analysis
Company Description
Range Cancer Therapeutics ETF (NASDAQ: CNCR) is a publicly traded company.
CNCR stock has declined 37.4% over the past year. Shares last traded at $9.32.
This page provides a comprehensive overview of CNCR stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Range Cancer Therapeutics ETF (CNCR) stock last traded at $9.32. Over the past 12 months, the stock has lost 37.4%.
Latest News
Range Cancer Therapeutics ETF has 1 recent news article. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. View all CNCR news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Range Cancer Therapeutics ETF (CNCR) currently stands at 6.4 thousand shares, down 6.5% from the previous reporting period, representing 0.8% of the float. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Range Cancer Therapeutics ETF (CNCR) currently stands at 2.7 days, down 11.9% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions.